Sana Q1 2025 Earnings Report
Key Takeaways
Sana Biotechnology reported a net loss of $49.4 million for the first quarter of 2025, a significant improvement compared to the $107.5 million loss in the same period last year. The company ended the quarter with $104.7 million in cash, cash equivalents, and marketable securities, with an expected cash runway into 2026. Sana highlighted positive clinical data for its type 1 diabetes program and progress in its allogeneic CAR T and in vivo CAR T pipelines.
Net loss for Q1 2025 was $49.4 million, a substantial decrease from $107.5 million in Q1 2024.
Ended Q1 2025 with $104.7 million in cash, cash equivalents, and marketable securities.
Presented positive 12-week clinical data for UP421 in type 1 diabetes, showing immune evasion and continued function.
Advancing clinical trials for SC291 in autoimmune diseases and SC262 in B-cell malignancies, with data expected in 2025.
Sana
Sana
Forward Guidance
Sana expects its current cash, cash equivalents, and marketable securities to provide a cash runway into 2026. The company anticipates filing INDs for SC451 in type 1 diabetes and SG299 in B-cell related diseases as early as 2026 and plans to report clinical data from the GLEAM and VIVID trials in 2025.
Positive Outlook
- Expected cash runway into 2026.
- Anticipate filing IND for SC451 in type 1 diabetes as early as 2026.
- Anticipate filing IND for SG299 in B-cell related diseases as early as 2026.
- Expect to report clinical data from the GLEAM trial (SC291 in autoimmune diseases) in 2025.
- Expect to report clinical data from the VIVID trial (SC262 in B-cell malignancies) in 2025.
Challenges Ahead
- No specific negative forward guidance was explicitly stated beyond the inherent risks of drug development and reliance on future funding.